Dong-A ST Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1932-01-01
- Employees
- 1.6K
- Market Cap
- -
- Website
- http://www.donga-st.com
Clinical Trials
114
Active:0
Completed:85
Trial Phases
5 Phases
Phase 1:62
Phase 2:10
Phase 3:18
+2 more phases
Drug Approvals
3
PHILIPPINES:3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (110 trials with phase data)• Click on a phase to view related trials
Phase 1
62 (56.4%)Phase 3
18 (16.4%)Phase 4
16 (14.5%)Phase 2
10 (9.1%)Not Applicable
4 (3.6%)A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
Not Applicable
Completed
- Conditions
- Acute GastritisChronic Gastritis
- Interventions
- Drug: Stillen® Tab PlaceboDrug: Stillen® Tab
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 212
- Registration Number
- NCT07139886
- Locations
- 🇰🇷
Ajou University Medical Center, Division of Gastroenterology, Suwon, Gyeonggi-do, Korea, Republic of
Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State
Not Applicable
Not yet recruiting
- Conditions
- Healthy
- Interventions
- Drug: DA-5222Drug: DA-5222-R1Drug: DA-5222-R2Drug: DA-5222-R3
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT07046715
A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: Diluted Intravenous DA-5217Drug: Undiluted Intravenous DA-5217
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07027982
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult Subjects
Phase 1
Recruiting
- Conditions
- Healthy Adult
- Interventions
- Drug: DA-5223(Fasting)Drug: DA-5223(Fed)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT07007520
- Locations
- 🇰🇷
CHA Global Clinical Trials Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Adult
- Interventions
- Drug: DA-5223-RDrug: DA-5223
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT07007533
- Locations
- 🇰🇷
CHA Global Clinical Trials Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 23
- Next
News
No news found